Nerandomilast, a PDE4 inhibitor, has shown significant efficacy in progressive pulmonary fibrosis (PPF), offering an ...

A recent setback due to unexpected safety concern from a phase 2 study to evaluate a STAT3 inhibitor in IPF patients refreshed an old debate regarding the feasibility to develop therapeutics targeting ...

Trevi Therapeutics stock (TRVI) earns a Buy rating as Haduvio advances toward phase 3 for chronic cough in IPF. Read the full ...

United Therapeutics is making headway in unlocking a new lung disease market for its drug Tyvaso (treprostinil) with a pivotal phase 3 win in idiopathic pulmonary fibrosis (IPF). United’s Teton-2 ...

FDA has granted orphan drug designation to FS2 (kynurenic acid) for the investigational treatment of idiopathic pulmonary ...

Mendelian randomization revealed a potential protective role of IPF against large artery atherosclerosis stroke, but no significant links with other cardiovascular diseases. The study suggests ...

Please provide your email address to receive an email when new articles are posted on . Almost 90% of Americans are unaware of the symptoms that signal pulmonary fibrosis due to the disease’s rarity, ...

SAN DIEGO--(BUSINESS WIRE)--Endeavor BioMedicines, a biotechnology company developing new treatments targeting the underlying causes of pulmonary fibrosis, today announced it has raised $62 million in ...

Christopher Kennedy's unexpected IPF diagnosis after a routine X-ray highlights the insidious nature of this lung disease.

This condition has been described by Michael J. Stephen in his 2021 book “Breath Taking” as the “most frustrating and disheartening of all the diseases in pulmonary medicine.” Over a frighteningly ...